Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536219

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536219

Cholangiocarcinoma Therapeutics

PUBLISHED:
PAGES: 182 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

Global Cholangiocarcinoma Therapeutics Market to Reach US$962.0 Million by 2030

The global market for Cholangiocarcinoma Therapeutics estimated at US$863.8 Million in the year 2023, is expected to reach US$962.0 Million by 2030, growing at a CAGR of 1.6% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$592.5 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 0.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$227.1 Million While China is Forecast to Grow at 1.3% CAGR

The Cholangiocarcinoma Therapeutics market in the U.S. is estimated at US$227.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$153.2 Million by the year 2030 trailing a CAGR of 1.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.5% CAGR.

Global Cholangiocarcinoma Therapeutics Market - Key Trends and Drivers Summarized

Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts. The disease is often diagnosed at an advanced stage due to its asymptomatic nature in the early phases, which complicates treatment and worsens prognosis. Standard treatment options for cholangiocarcinoma include surgery, chemotherapy, and radiation therapy. Surgery, particularly resection, offers the best chance for a cure, but it is only feasible in a minority of patients due to the late presentation of the disease. For unresectable or metastatic cases, chemotherapy regimens typically include combinations such as gemcitabine with cisplatin, although these treatments primarily aim to prolong survival rather than cure the disease. Recently, the advent of targeted therapies and immunotherapies has provided new avenues for treatment, giving hope to patients with advanced cholangiocarcinoma.

The landscape of cholangiocarcinoma therapeutics has been significantly transformed by advances in molecular biology and genetics, leading to the development of targeted therapies. These therapies are designed to attack specific genetic mutations or alterations that drive cancer growth. For instance, FGFR2 (fibroblast growth factor receptor 2) fusions and IDH1 (isocitrate dehydrogenase 1) mutations are found in a subset of cholangiocarcinoma patients and have become targets for novel drugs. Pemigatinib and infigratinib, both FGFR inhibitors, have shown efficacy in clinical trials, offering new treatment options for patients with FGFR2 fusions. Similarly, ivosidenib, an IDH1 inhibitor, has demonstrated benefits for patients with IDH1-mutant cholangiocarcinoma. Immunotherapy, particularly checkpoint inhibitors like pembrolizumab, is also being explored, although the response rates in cholangiocarcinoma have been modest compared to other cancers. Ongoing clinical trials are investigating combinations of these therapies to enhance their effectiveness and overcome resistance mechanisms.

The growth in the cholangiocarcinoma therapeutics market is driven by several factors. The increasing incidence of cholangiocarcinoma, partly attributed to rising rates of liver diseases and infections such as hepatitis B and C, is expanding the patient population in need of treatment. Technological advancements in genomic profiling and personalized medicine are facilitating the identification of actionable mutations, thereby driving the development and adoption of targeted therapies. Furthermore, substantial investment in research and development by pharmaceutical companies is leading to a robust pipeline of novel therapeutics. Regulatory support and expedited approval processes for orphan drugs are also propelling market growth, as these incentives encourage the development of treatments for rare diseases like cholangiocarcinoma. Additionally growing awareness among healthcare professionals and patients about the potential of targeted and combination therapies is boosting demand. As these trends continue to evolve, the cholangiocarcinoma therapeutics market is poised for significant expansion, driven by technological advancements, a deeper understanding of cancer biology, and a strong focus on innovative treatment strategies.

Select Competitors (Total 86 Featured) -

  • Bold Therapeutics
  • CStone Pharmaceuticals
  • Genfit SA
  • J-Pharma Co., Ltd.
  • Lisata Therapeutics
  • Owkin, Inc.
  • RedHill Biopharma Ltd.
  • RenovoRx, Inc.
  • Servier Laboratories
  • Specialised Therapeutics Australia Pty Limited
  • Taiho Pharmaceutical Co., Ltd.
  • Tempest Therapeutics
  • TriSalus Life Sciences
  • Tyra Biosciences;
Show more
Product Code: MCP26833

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Cholangiocarcinoma Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Cholangiocarcinoma Expands Addressable Market Opportunity
    • Advances in Genomic Profiling Propel Development of Targeted Therapies
    • Rising Rates of Liver Diseases and Hepatitis Infections Drive Demand for Treatments
    • Technological Innovations in Personalized Medicine Strengthen Business Case for Novel Therapies
    • Growing Awareness of Targeted and Combination Therapies Accelerates Market Adoption
    • Identification of Actionable Genetic Mutations Throws Spotlight on Precision Medicine
    • Increasing Use of FGFR and IDH1 Inhibitors Drives Market Expansion
    • Exploration of Immunotherapy Combinations Generates New Opportunities
    • Challenges in Early Diagnosis and Late-Stage Presentation Propel Need for Advanced Therapeutics
    • Integration of Biomarker Testing in Treatment Planning Enhances Efficacy
    • Rising Healthcare Expenditure Expands Reach of Therapies
    • Focus on Overcoming Resistance Mechanisms Sustains Growth in Therapeutic Development
    • Adoption of Precision Oncology Approaches Drives Development of Personalized Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cholangiocarcinoma Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cholangiocarcinoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Cholangiocarcinoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!